SpecialFocus
Engineering Thermoplastics
Lead the Way in Struggle against Global Pandemic
MEDICAL
By Fran Alder and Bruce Dickinson
N

othing has demonstrated the importance of plastics in medical applications quite as clearly as the events of 2020 resulting from the global COVID-19 pandemic. The performance plastics industry was quick to mobilize and step up to meet the needed demand for personal protective equipment (PPE) such as face shields, as well as clear sheet material for barriers that helped essential businesses protect their customers and employees and safely reopening the economy. Not far behind came the need for source controlled and suitable materials such as polyetheretherketone (PEEK) and acetal copolymer (POM C) for ventilator components to care for the critically ill from the COVID-19 virus. And now, to defeat the virus through the use of vaccines and therapeutics, the pharmaceutical industry is looking to the performance plastics industry for the appropriate materials for single use processing alternatives in developing the cure.

As pharmaceutical companies are stepping up the development of cures and treatments for COVID-19 with government direction, new demand for processing equipment is increasing. Filling this demand has been supported with government directives such as Operation Warp Speed in the United States which is designed to ensure priorities are given by manufacturers to key development components in the fight against the virus. Components in direct contact with bio pharmaceutical products are typically single use to avoid cross contamination between batches. Special needs for the performance plastics filling these applications are chemical resistance to solvents commonly used in the process, low extractable potential from the materials and gamma stability, since gamma radiation is the predominant method of sterilization for these components. The materials also need to be source controlled to eliminate any variables in the ongoing manufacturing process. Some of the materials fitting these requirements are PEEK, polyphenylsulfone (PPSU), polysulfone (PSU), polyetherimide (PEI), polypropylene (PP), polycarbonate (PC) and acrylic (PMMA). Recently, a new clear material has been introduced that addresses some of the short comings of polycarbonate and acrylic, while maintaining all their key benefits.

An Ensinger TECADUR® MT TR natural manifold block for biopharmaceutical processing.
An Ensinger TECADUR® MT TR natural manifold block for biopharmaceutical processing.
This new material is a transparent copolyester (poly cyclohexylenedimethylene yerephthalate glycol-modified, or PCT-G) polymer that exhibits high impact properties along with very low extractable levels and very high gamma stability, with no color change post exposure. Although it exhibits many of the properties of polycarbonate, it does not have the negative issue of BPA additives. The resin has been tested to and is compliant with the requirements for USP Class VI. Stock shapes are available that have been tested to ISO 10993 for blood and tissue contact. However, for application in the pharmaceutical industry, this testing may not be enough.
Ensinger TECAFIL filament spools for additive manufacturing.
Ensinger TECAFIL filament spools for additive manufacturing.
The BioPhorum Operations Group (BPOG) has also defined a guideline for pharmaceutical end use products to evaluate materials’ compatibility with certain solvents often encountered in this industry. The guideline is called the “Standardized Extractable Testing Protocol for Single Use Systems in Bio Manufacturing,” the testing for which is usually somewhat expensive. Therefore, device manufacturers typically want to be very sure all of their device components are likely to pass the testing prior to risking that expense. To that end, they may want to search for component materials that have been screened by the manufacturer in order to estimate the likelihood of compatibility with the solvents specified in the BPOG Standard Extractable Protocol. A typical screening should consist of tensile test bars being pre-treated with gamma radiation and then stored for 24 hours in each solvent. After exposure, the bars can be tested for weight difference, solvent PH, shore D and tensile test values to determine any significant chemical effects. This type of pre-screening can give device manufacturers a much higher level of confidence that the materials as screened will likewise perform in a similar fashion in the end use application.

Typical applications include manifolds and valve components; single use sensors for pH detection, temperature and flow; simple sleeve bearings for moving components such as impellers, as well as the impeller itself; and microfluidic blocks used in the analysis of liquid substrate of various kinds. Manufacturing methods for producing the finished single use device include injection molding, machining from extruded stock shapes and, more recently, even additive manufacturing or 3D printing. The chosen process comes down to economics: If there is enough volume to justify the cost of an injection molding tool, then a molded part makes sense. Some part geometries such as manifolds are best to machine from stock shapes, while additive manufacturing expands design possibilities to include features that cannot be accommodated by machining or injection molding. For example, features such as internal undercuts are best accomplished through the use of 3D printing. Additive manufacturing provides customization and feature complexity with little additional cost within the process. Fortunately, the same thermoplastic material portfolio for these applications are available to designers as an injection molding resin, a stock shape for machining, as well as additive manufacturing filaments.

The speed at which the performance plastics industry has been able to respond and react to the unique environment created by this world pandemic is yet another example of our industry’s unique ability to quickly adapt, innovate and deploy solutions to industries’ most challenging problems.

Fran Alder is the medical industry specialist and Bruce Dickinson is the division manager marketing and product management for Ensinger Inc. For more information, contact Ensinger Inc. at 365 Meadowlands Boulevard, Washington, PA 15301-8904 USA; phone (724) 746-6050 or (800) 243-3221, fax (724) 746-9209; sales@ensinger-ind.com or www.ensingerplastics.com.